Skip to Main Content
Contribute Try STAT+ Today

Moderna (MRNA) has halted a rancorous patent dispute with the U.S. government over assigning credit for its Covid-19 vaccine, saying the ongoing quarrel “could interfere with further discussions aimed at an amicable resolution” with the National Institutes of Health.

The move comes amid intensifying complaints that many vaccine makers are failing to make their intellectual property available so that still other companies can produce vaccines needed for a global eradication campaign. Moderna, which recently projected $18 billion in vaccine sales this year, has been a particular focus of criticism because U.S. taxpayers provided $2.5 billion to help develop the shot.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment